Terminal › Stocks › IVVD

Invivyd, Inc. (IVVD) Stock

Healthcare · Biotechnology · US

$1.78 +31.85%

Last updated Jun 18, 2026 23:56 UTC

IVVD Key Statistics

Market Cap$236.26M

P/E (TTM)-4.68

P/S (TTM)4.42

P/B (TTM)1.27

Revenue (TTM)$53.43M

EPS (TTM)$-0.38

Dividend Yield—

ROE (TTM)-48.65%

Net Margin-98.25%

Gross Margin92.99%

52W High$2.04

52W Low$1.17

Analyst ViewBuy

Price Target$9.50

Employees99

Volume12,901,863

About Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

CEO: William E. Duke Jr.. Company website

See IVVD live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open IVVD in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.